↓ Skip to main content

American Association for Cancer Research

Opium Use and Risk of Pancreatic Cancer: A Prospective Cohort Study

Overview of attention for article published in Cancer Epidemiology, Biomarkers & Prevention, March 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
7 news outlets
twitter
8 X users

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
39 Mendeley
Title
Opium Use and Risk of Pancreatic Cancer: A Prospective Cohort Study
Published in
Cancer Epidemiology, Biomarkers & Prevention, March 2018
DOI 10.1158/1055-9965.epi-17-0592
Pubmed ID
Authors

Shirin Moossavi, Mehdi Mohamadnejad, Akram Pourshams, Hossein Poustchi, Farhad Islami, Maryam Sharafkhah, Babak Mirminachi, Siavosh Nasseri-Moghaddam, Shahryar Semnani, Ramin Shakeri, Arash Etemadi, Shahin Merat, Masoud Khoshnia, Sanford M. Dawsey, Paul D. Pharoah, Paul Brennan, Christian C. Abnet, Paolo Boffetta, Farin Kamangar, Reza Malekzadeh

Abstract

We examined the association between opium consumption and pancreatic cancer incidence in a large-scale prospective cohort of the general population in Northeast of Iran. A total of 50,045 adults were systematically followed-up (median of 7.4 years) and incident cases of pancreatic cancer were identified. Self-reported data on opium consumption was collected at baseline. Cumulative use (-year) was defined as number of nokhods (a local unit, approximately 0.2 g) of opium consumed per day multiplied by number of years consuming. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between opium consumption and pancreatic cancer were calculated using Cox proportional hazards regression models. Overall, 54 confirmed cases of pancreatic cancer were identified. Opium use of more than 81 nokhod-years (high cumulative use), compared to never use, was strongly associated with pancreatic cancer even after adjustments for multiple potential confounding factors [HR=3.01; 95% CI 1.25-7.26]. High cumulative consumption of opium was significantly associated with risk of pancreatic cancer after adjusting for cumulative dose of cigarette smoking [HR=3.56; 95% CI 1.49-8.50]. In a sensitivity analysis, we excluded participants (including 2 pancreatic cancer cases) who were recruited within the first 5 years of starting opium consumption; high cumulative use of opium was still associated with pancreatic cancer risk [HR=2.75; 95% CI 1.14-6.64]. Our results showed a positive association between opium consumption and pancreatic cancer. This is the first prospective large-scale study to show the association of opium consumption with pancreatic cancer as a risk factor.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 15%
Researcher 5 13%
Professor 5 13%
Professor > Associate Professor 4 10%
Other 3 8%
Other 4 10%
Unknown 12 31%
Readers by discipline Count As %
Medicine and Dentistry 9 23%
Biochemistry, Genetics and Molecular Biology 3 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Nursing and Health Professions 2 5%
Agricultural and Biological Sciences 2 5%
Other 5 13%
Unknown 16 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 51. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2023.
All research outputs
#832,584
of 25,576,801 outputs
Outputs from Cancer Epidemiology, Biomarkers & Prevention
#307
of 4,855 outputs
Outputs of similar age
#18,691
of 345,357 outputs
Outputs of similar age from Cancer Epidemiology, Biomarkers & Prevention
#6
of 65 outputs
Altmetric has tracked 25,576,801 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,855 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,357 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.